Cort
Phoenix Rising Founder
- Messages
- 7,391
These findings should encourage the health community to recognise the disabling effects of ME/CFS, to advocate for the needs of people with ME/CFS, and to investigate strategies to address the cost of the disease to both individuals and society. The authors
M.S. of course is one of the most fatiguing and debilitating diseases known but its got nothing on ME/CFS when it comes to whacking a person where it really hurts - their functioning. I've read several times that for many people with MS their most disabling symptom is fatigue.
That's too bad but ME/CFS patients were actually significantly worse off.....
I don't recognize these London researchers but they did a great job highlighting how devastating ME/CFS is. ME/CFS patients scored not just lower but significantly lower in almost all the SF-36 functional domains and people with ME/CFS were particularly impaired with their ability to participate in physical activities.
What a great advocacy tool this study is...
(The best is still the huge 1996 Komaroff study which found reduced functional status compared to congestive heart failure (n = 216), type II diabetes mellitus (n = 163), acute myocardial infarction (n = 107), multiple sclerosis (n = 25), and depression (n = 502).
https://www.ncbi.nlm.nih.gov/pubmed/8873490)
It's great to see a more up to date study, though.
Pharmacoecon Open. 2018 Mar 13. doi: 10.1007/s41669-018-0071-6. [Epub ahead of print]
Functional Status and Well-Being in People with Myalgic Encephalomyelitis/Chronic FatigueSyndrome Compared with People with Multiple Sclerosis and Healthy Controls.
Kingdon CC1, Bowman EW2, Curran H2, Nacul L2, Lacerda EM2.
Author information
Abstract
BACKGROUND:
People with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) continue to struggle to have their condition recognised as disabling in the face of public and professional prejudice and discrimination.
OBJECTIVE:
The aim of this study was to compare the functional status and well-being of people with well-characterised ME/CFS with people with multiple sclerosis (PWMS), as well as healthy controls (HCs).
METHODS:
In this cross-sectional study, we used data collected as part of the UK ME/CFS Biobank to compare actual participant scores from the Medical Outcomes Survey Short Form-36 v2™ (SF-36v2™) between groups, as a proxy for impact of disability, and from a bespoke questionnaire seeking data on employment and income.
RESULTS:
People with ME/CFS scored significantly lower than PWMS or HCs in almost all SF-36v2™ areas. Prominent were lower scores for people with ME/CFS in the Physical Component Summary and Role Physical and Social Function domains, while the smallest differences were seen in the Mental Health domain. Responses to the bespoke questionnaire indicated that people with ME/CFS in this study work fewer hours and have lower incomes compared with people in the other two groups.
CONCLUSIONS:
Using SF-36v2™ scores as a proxy, people with ME/CFS were measurably more disabled than PWMS or HCs in this study population. Furthermore, employment and income data are consistent with loss of functional status. These findings should encourage the health community to recognise the disabling effects of ME/CFS, to advocate for the needs of people with ME/CFS, and to investigate strategies to address the cost of the disease to both individuals and society.